We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abcam Plc | LSE:ABC | London | Ordinary Share | GB00B6774699 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,226.00 | 1,240.00 | 1,246.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMABC
RNS Number : 2593E
ABCAM Plc
06 February 2015
For immediate release 6 February 2015
ABCAM PLC
("Abcam" or "the Company")
Block Admission Return
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: Abcam plc ---------------------------------------------------------------------------- ---------------------------------------- Name of scheme: 1. Abcam EMI Scheme 2. Abcam SAYE Scheme 3. Abcam 2005 Share Option Scheme 4. Abcam Share Incentive Plan 5. Abcam Company Share Option Plan 6. Abcam Long Term Incentive Plan 7. Annual Bonus Plan ---------------------------------------------------------------------------- ---------------------------------------- Period of return: From: 6 August 2014 To: 5 February 2015 ---------------------------------------------------- ---------------------- --------------- ----- ---------------- Balance of unallotted securities under scheme(s) from previous return: 1. 568,815 2. 31,405 3. 2,775,259 4. 464,586 5. 727,253 6. 2,036,053 7. 399,479 ---------------------------------------------------------------------------- ---------------------------------------- Plus: The amount by which the block scheme(s) has been increased since the 1. - date of the last 2. - return (if any increase has been applied for): 3. - 4. - 5. - 6. - 7. - ---------------------------------------------------------------------------- ---------------------------------------- Less: Number of securities issued/allotted under scheme(s) during period 1. 7,900 (see LR3.5.7G): 2. - 3. 114,950 4. 183,440 5. 44,015 6. 70,304 7. - ---------------------------------------------------------------------------- ---------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1. 560,915 2. 31,405 3. 2,660,309 4. 281,146 5. 683,238 6. 1,965,749 7. 399,479 ---------------------------------------------------------------------------- ---------------------------------------- Name of contact: Laura Taylor, Investor Relations ------------------------------ --------------------------------- Telephone number of contact: 01223 696000 ------------------------------ ---------------------------------
For further information please contact:
+ 44 (0) 1223 Abcam 696 000 Jeff Iliffe, Chief Financial Officer Laura Taylor, Investor Relations Manager J.P.Morgan Cazenove - Nominated Adviser & Joint + 44 (0) 20 7742 Corporate Broker 4000 James Mitford / Alex Bruce - Nominated Adviser + 44 (0) 20 7418 Peel Hunt LLP - Joint Corporate Broker 8900 Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking +44 (0) 20 7404 Brunswick 5959 Justine Mcllroy / Will Medvei / Anna Carruth
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRGCGDDCDGBGUL
1 Year Abcam Chart |
1 Month Abcam Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions